Perspective Therapeutics (CATX) Non-Current Deffered Revenue (2024 - 2026)

Perspective Therapeutics' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $26.6 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue changed 0.0% year-over-year to $26.6 million; the TTM figure through Mar 2026 stood at $26.6 million (changed 0.0% YoY), while the FY2025 annual figure was $26.6 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue came in at $26.6 million for Q1 2026 at Perspective Therapeutics, roughly flat from $26.6 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $26.6 million in Q1 2024 to a low of $26.6 million in Q1 2024.
• A 3-year average of $26.6 million and a median of $26.6 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• On a YoY basis, Non-Current Deffered Revenue climbed as much as 0.0% in 2025 and fell as far as 0.0% in 2025.
• Perspective Therapeutics' Non-Current Deffered Revenue stood at $26.6 million in 2024, then changed by 0.0% to $26.6 million in 2025, then changed by 0.0% to $26.6 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $26.6 million, $26.6 million, and $26.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison